Aug 2 2006, 2:21 AM EST
News source: Business Wire
ALTANA AG (NYSE:AAA)(FWB:ALT)(GER:ALT):-- ALTANA Pharma: Sales +13%, operating return 30%
-- ALTANA Chemie: Sales +56%, operating return 19%
-- Outlook for 2006 confirmed: On the way to 11th record year in succession
ALTANA AG (NYSE:AAA)(FWB:ALT)(GER:ALT) increased first-half consolidated sales in 2006 by 24% to EUR 1.93 billion. This growth is due to the very good operating performance of ALTANA Pharma and ALTANA Chemie. The acquisition of the ECKART Group also contributed to this excellent development. Adjusted for currency and acquisition/divestment effects, operating sales increased by 10%. "Our first half-year performance provides impressive confirmation that we are on the way to achieving our ambitious growth goals set for the whole of 2006," commented Dr. Nikolaus Schweickart, President and CEO of ALTANA AG.
Good growth rates were achieved in international markets, in particular. EUR 1.6 billion of the total sales were generated outside Germany. This is equivalent to an increase of 28% on the prior year and a foreign sales share of 84%. Domestic sales in the first half-year amounted to EUR 305 million, up 10% on the prior year's figure. Particularly strong growth figures were achieved in the market regions of North America, where sales increased by 39% to EUR 592 million; in Latin America, with an increase in sales of 36% to EUR 197 million, and Asia, with sales up by 37% to EUR 188 million. European sales outside Germany climbed by 15% to EUR 622 million.
ALTANA's earnings before taxes (EBT) rose by 8% to EUR 382 million. This growth rate was influenced by a special effect: Earnings before taxes (EBT) in the second quarter of 2006 comprise a one-time expense amounting to EUR 25 million for the redemption of various employee incentive programs due to the intended restructuring of the Group. Excluding this special effect, earnings before taxes (EBT) grew by 16%.
First-half operating earnings measured in terms of EBITDA totaled EUR 466 million, 14% more than in the prior year; EBIT amounted to EUR 379 million, up 9% on the prior year, and first-half net income totaled EUR 244 million, up 11% on the prior year's figure.
The operating return (EBITDA) was 24.1% in the first half of 2006. The return on sales before taxes (EBT) was 19.8%. Earnings per share (EPS) rose by 11% to EUR 1.79.
In the period under review, ALTANA's capital expenditure on property, plant and equipment and on intangible assets rose by 42% to EUR 93 million. The company's research expenses grew by 14% to EUR 245 million. As of June 30, 2006, ALTANA employed about 13,500 people worldwide, an increase of 21% on the first half of 2005, mostly due to acquisitions. Of the total workforce, about 6,400 were employed in Germany and about 7,000 abroad.
ALTANA Group: Outlook for 2006 confirmed
At Group level, we anticipate growth in sales of about 20% for 2006 as a whole, with a business volume of almost EUR 4 billion. Earnings (EBT) before special expenses for the restructuring of the Group are expected to be some 8-10% higher than last year.
The process of the long-term development of the two divisions is underway. "We are right on course. We are striving to achieve a strategically long-term solution which we are discussing with potential partners. At the same time, preparations for an independent operation of the chemicals business are underway. From today's perspective, we will, as announced, take the decisive decisions and determine the direction of both processes in the course of this year," explained Dr. Nikolaus Schweickart, President and CEO of ALTANA AG.
ALTANA Pharma: Strong international business with top-level return figures
ALTANA
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All